What are the specific design principles for small molecules that can selectively modulate pathological vs. physiological TDP-43 phase separation?

PARTIALLY ADDRESSED

The debate identified that TDP-43 undergoes both normal and pathological phase separation, but no clear molecular criteria were established for designing therapeutics that preserve normal function while preventing aggregation. This represents a critical gap for rational drug design. Source: Debate session sess_sda-2026-04-01-gap-006 (Analysis: sda-2026-04-01-gap-006)

Priority: 0.90 Domain: medicinal-chemistry Hypotheses: 0

📊 Landscape Analysis

Landscape Summary: What are the specific design principles for small molecules that can selectively modulate pathological vs. physiological TDP-43 phase separation? is a 0.9 priority gap in medicinal-chemistry. It has 0 linked hypotheses with average composite score 0.000. Status: partially_addressed.

Key Unanswered Questions

What is the optimal TREM2 modulation strategy across disease stages?
How does DAM activation state affect therapeutic outcomes?
What biomarkers predict response to TREM2-targeted interventions?

Key Researchers

Colonna, Sevlever, et al. (TREM2 biology)

Clinical Trials

What are the specific design principles for small molecules that can selectively modulate pathological vs. physiological TDP-43 phase separation? — INVOKE-2 (completed)

📈 Living Dashboards

0

Hypotheses

0.000

Top Score

0.000

Avg Score

0

Debates

0.00

Avg Quality

60%

Resolution

0

Mechanistic Families

Gap Resolution Progress60%

Hypothesis Score Distribution

🏆 Competing Hypotheses (Ranked by Score)

No hypotheses linked to this gap yet.

🌊 Knowledge Graph Connections

activates (1)

STEM CELLS→TDP-43

associated with (7)

TARDBP→TDP-43TDP-43→Frontotemporal Lobar DegenerationTDP-43→FTLD-TDPTDP-43→ALS/FTLDTDP-43→Ad

▸ Show 2 more

TDP-43→TDP-43 K181ETDP-43→Mitochondrial DNA Release

binds (5)

TDP-43→LDLRTDP-43→SREBF2TDP-43→HMGCRTDP-43→HMGCS1TDP-43→UG-rich RNA sequences

biomarker for (1)

TDP-43→frontotemporal lobar degeneration

causes (5)

TDP-43→AGGREGATIONTDP-43→Frontotemporal DementiaTDP-43→RNA DysregulationTDP-43→Nuclear DepletionTDP-43→Cytoplasmic Aggregation

conjugates (1)

SUMO2/3→TDP-43

inhibits (3)

TDP-43→Cryptic Exon SplicingTDP-43→UNC13ATDP-43→Cryptic Exon Inclusion

interacts with (6)

entities-histone-modifications→TDP-43entities-mitochondrial-dynamics→TDP-43TREM2→TDP-43NEURON→TDP-43TAU→TDP-43

▸ Show 1 more

14-3-3θ→TDP-43

involved in (5)

TDP-43→Nuclear CondensationTDP-43→Tdp-43 ProteinopathiesStress Granules→TDP-43TDP-43→AggregationTDP-43→RNA Splicing

phosphorylates (1)

p38α MAPK→TDP-43

regulates (15)

TDP-43→RNA bindingTDP-43→STABILITYTDP-43→oligomerizationTDP-43→NEAT1TDP-43→Cryptic Splicing

▸ Show 10 more

TDP-43→Splicing RepressionASRGL1→TDP-43TDP-43→mRNA SplicingTDP-43→Alternative SplicingTDP-43→KCNQ2TDP-43→LC3ylationTDP-43→UNC13AcAMP/PKA Signaling→TDP-43TDP-43→Gene ExpressionTDP-43→PKN1

🕑 Activity Feed

✏ update on knowledge_gap by None 2026-04-21T14:21

💬 Discussion

No discussions yet. Be the first to comment.

📋 Investigation Sub-Tasks

Create sub-tasks to investigate specific aspects of this gap:

Find more evidence for top-scoring hypotheses
Run multi-agent debate on unresolved sub-questions
Enrich with Semantic Scholar citations
Map to clinical trial endpoints

← Back to All Gaps